{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T07:30:31Z","timestamp":1772609431883,"version":"3.50.1"},"reference-count":24,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T00:00:00Z","timestamp":1671753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Patients with peripheral arterial disease (PAD) are at high risk of major adverse cardiac events (MACE) and major adverse limb events (MALE). Recently, antithrombotic therapies employing antiplatelet and anticoagulant drugs have proven to be valid in reducing MACE in patients with PAD and polyvascular disease and MALE, particularly in patients who have already been revascularized and remain at increased risk of MALE. However, more aggressive antithrombotic therapies lead to an increased risk of bleeding. Antithrombotic therapy and revascularization procedures entail an increased hemorrhagic risk that is also linked to having received more vigorous antithrombotic therapies. Therefore, it appears crucial to have specifically targeted scores for a PAD patient to assess bleeding and thrombotic risks. The correct utilization of a risk score will determine the variable risk factors for bleeding that can be corrected or modified, as well as identify patients at high risk that require regular reexamination and follow-up. Clinical risk scores do not represent the absolute reality, and inter-score variability must be taken into account. Moreover, several risk scores have been created to be basic and to facilitate and improve clinical decisions in daily practice. Many risk scores based on points vary according to the configuration of the studies, population type, and ethnic group, and many of the risk factor elements in a specific score are unlikely to sustain same weight for that risk. The best approach continues to be devising an uncomplicated, functional, validated, and precise score that can be adjusted to different clinical contexts and populations, while considering the mutable composition of clinical risk.<\/jats:p>","DOI":"10.3390\/life13010047","type":"journal-article","created":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T04:58:01Z","timestamp":1672117081000},"page":"47","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Bleeding Risk in Patients with Peripheral Arterial Disease"],"prefix":"10.3390","volume":"13","author":[{"given":"Adriana","family":"Vison\u00e0","sequence":"first","affiliation":[{"name":"Angiology Unit, Azienda ULSS 2 Marca Trevigiana, 31033 Castelfranco Veneto, TV, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Zurlo","sequence":"additional","affiliation":[{"name":"Angiology Unit, Azienda ULSS 2 Marca Trevigiana, 31033 Castelfranco Veneto, TV, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Panzavolta","sequence":"additional","affiliation":[{"name":"Angiology Unit, Azienda ULSS 2 Marca Trevigiana, 31033 Castelfranco Veneto, TV, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annachiara","family":"Gobbo","sequence":"additional","affiliation":[{"name":"Angiology Unit, Azienda ULSS 2 Marca Trevigiana, 31033 Castelfranco Veneto, TV, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beniamino","family":"Zalunardo","sequence":"additional","affiliation":[{"name":"Angiology Unit, Azienda ULSS 2 Marca Trevigiana, 31033 Castelfranco Veneto, TV, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(13)61249-0","article-title":"Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: A systematic review and analysis","volume":"382","author":"Fowkes","year":"2013","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jacc.2019.11.050","article-title":"Long-term outcomes and associations with major adverse limb events after peripheral artery revascularization","volume":"75","author":"Hess","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e009584","DOI":"10.1161\/CIRCINTERVENTIONS.120.009584","article-title":"Contemporary Review of Antithrombotic Therapy in Peripheral Artery Disease","volume":"13","author":"Hess","year":"2020","journal-title":"Circ. Cardiovasc. Interv."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","article-title":"Rivaroxaban in Peripheral Artery Disease after Revascularization","volume":"382","author":"Bonaca","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_6","first-page":"1","article-title":"ESVM Guideline on peripheral arterial disease","volume":"48","author":"Frank","year":"2019","journal-title":"Vasa"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.1093\/eurheartj\/ehab390","article-title":"Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: A consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombosis, and the ESC working group on cardiovascular pharmacotherapy","volume":"42","author":"Aboyans","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1024\/0301-1526\/a000969","article-title":"Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease","volume":"50","author":"Belch","year":"2021","journal-title":"Vasa"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.jacc.2019.07.065","article-title":"Major Bleeding in Patients with Coronary or Peripheral Artery Disease Treated with Rivaroxaban Plus Aspirin","volume":"74","author":"Eikelboom","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e008069","DOI":"10.1161\/CIRCINTERVENTIONS.119.008069","article-title":"Impact of Procedural Bleeding in Peripheral Artery Disease: An Analysis From EUCLID Trial","volume":"12","author":"Kansal","year":"2019","journal-title":"Circ. Cardiovasc. Interv."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.jvs.2022.04.048","article-title":"Increased long-term bleeding complications in females undergoing endovascular revascularization for peripheral arterial disease","volume":"76","author":"Marulanda","year":"2022","journal-title":"J. Vasc. Surg."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1024\/0301-1526\/a000998","article-title":"European Society of Vascular Medicine. Management of chronic peripheral artery disease patients with indication for endovascular revascularization","volume":"51","author":"Heiss","year":"2022","journal-title":"Vasa"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1161\/CIRCRESAHA.121.318258","article-title":"Contemporary Medical Management of Peripheral Artery Disease","volume":"128","author":"Bonaca","year":"2021","journal-title":"Circ. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1161\/CIRCULATIONAHA.109.858365","article-title":"Bleeding increases the risk of ischemic events in patients with peripheral arterial disease","volume":"120","author":"Algra","year":"2009","journal-title":"Circulation"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.ahj.2005.04.017","article-title":"Clinical classification schemes for predicting hemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF)","volume":"151","author":"Gage","year":"2006","journal-title":"Am. Heart J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1093\/eurheartj\/ehz372","article-title":"Defining high bleeding risk in patients undergoing percutaneous coronary intervention: A consensus document from the Academic Research Consortium for High Bleeding Risk","volume":"40","author":"Urban","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1161\/STROKEAHA.107.504993","article-title":"Bleeding with Antithrombotic Therapy (BAT) Study Group. Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease: A prospective, multicenter, observational study","volume":"39","author":"Toyoda","year":"2008","journal-title":"Stroke"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1161\/CIRCULATIONAHA.106.612812","article-title":"Adverse impact of bleeding on prognosis in patients with acute coronary syndromes","volume":"114","author":"Eikelboom","year":"2006","journal-title":"Circulation"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1093\/eurheartj\/ehq021","article-title":"Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis","volume":"31","author":"Ducrocq","year":"2010","journal-title":"Eur. Heart J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1177\/1526602816637621","article-title":"Bleeding Risk Profile in Patients with Symptomatic Peripheral Artery Disease","volume":"23","author":"Baumann","year":"2016","journal-title":"J. Endovasc. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1055\/s-0038-1646923","article-title":"Predictors of Bleeding in Patients with Symptomatic Peripheral Artery Disease: A Cohort Study Using The Health Improvement Network in the United Kingdom","volume":"118","author":"Fowkes","year":"2018","journal-title":"Thromb. Haemost."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1093\/eurheartj\/ehz404","article-title":"Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: Results from the COMPASS trial","volume":"40","author":"Eikelboom","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ejvs.2021.12.019","article-title":"The OAC3-PAD Risk Score Predicts Major Bleeding Events one Year after Hospitalisation for Peripheral Artery Disease","volume":"63","author":"Behrendt","year":"2022","journal-title":"Eur. J. Vasc. Endovasc. Surg."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/13\/1\/47\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:49:43Z","timestamp":1760147383000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/13\/1\/47"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,23]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["life13010047"],"URL":"https:\/\/doi.org\/10.3390\/life13010047","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,23]]}}}